DAWN
Day One Biopharmaceuticals, Inc. Healthcare - Biotechnology Investor Relations →
Day One Biopharmaceuticals, Inc. (DAWN) closed at $11.41 as of 2026-02-02, trading 14.5% below its 200-week moving average of $13.35. This places DAWN in the extreme value zone. The stock moved further from the line this week, up from -16.4% last week. The 14-week RSI sits at 66, indicating neutral momentum.
Over the past 197 weeks of data, DAWN has crossed below its 200-week moving average 3 times. On average, these episodes lasted 54 weeks. Historically, investors who bought DAWN at the start of these episodes saw an average one-year return of +19.6%.
With a market cap of $1172 million, DAWN is a small-cap stock. Free cash flow yield is currently negative, meaning the company is burning cash. Return on equity stands at -30.2%. The stock trades at 2.6x book value.
Share count has increased 63.2% over three years, indicating dilution.
Over the past 3.8 years, a hypothetical investment of $100 in DAWN would have grown to $162, compared to $176 for the S&P 500. DAWN has returned 13.5% annualized vs 15.9% for the index, underperforming the broader market over this period.
Free cash flow has been declining. A deteriorating cash flow trend warrants extra scrutiny — the stock may be cheap for a reason.
Growth of $100: DAWN vs S&P 500
Monthly data normalized to $100 at start. Vertical dashed lines mark 200-week MA touches.
What Happens After DAWN Crosses Below the Line?
Across 3 historical episodes, buying DAWN when it crossed below its 200-week moving average produced an average return of +20.7% after 12 months (median -7.0%), compared to +15.3% for the S&P 500 over the same periods. 33% of those episodes were profitable after one year. After 24 months, the average return was +6.0% vs +41.3% for the index.
Each line shows $100 invested at the moment DAWN crossed below its 200-week MA. Bold blue = stock average. Gray dashed = S&P 500 average over same periods.
Historical Touches
DAWN has crossed below its 200-week MA 3 times with an average 1-year return of +19.6% after recovery.
| Crossed Below | Recovered | Weeks | Max Depth | 1-Year Return | Return Since Touch |
|---|---|---|---|---|---|
| May 2022 | Jun 2022 | 7 | 68.1% | +62.9% | +35.8% |
| Jul 2022 | Aug 2022 | 1 | 2.6% | -23.6% | -33.4% |
| Feb 2023 | Ongoing | 155+ | 59.5% | Ongoing | -36.6% |
| Average | 54 | — | +19.6% | — |
Not financial advice. This is an educational tool. Past performance does not guarantee future results. Do your own research before making investment decisions.
Data as of Friday close, 2026-02-02